GB9120306D0
(en)
|
1991-09-24 |
1991-11-06 |
Graham Herbert K |
Method and compositions for the treatment of cerebral palsy
|
US6974578B1
(en)
*
|
1993-12-28 |
2005-12-13 |
Allergan, Inc. |
Method for treating secretions and glands using botulinum toxin
|
EP1147776B1
(en)
*
|
1993-12-28 |
2010-12-15 |
Allergan, Inc. |
Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
|
US8187612B2
(en)
|
1993-12-28 |
2012-05-29 |
Allergan, Inc. |
Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
|
US8557256B2
(en)
|
1993-12-28 |
2013-10-15 |
Allergan, Inc. |
Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
|
US20040126396A1
(en)
*
|
1993-12-28 |
2004-07-01 |
Allergan, Inc. |
Botulinum toxin treatment for strabismus
|
US5721215A
(en)
*
|
1996-03-20 |
1998-02-24 |
Allergan |
Injectable therapy for control of muscle spasms and pain related to muscle spasms
|
US6063768A
(en)
*
|
1997-09-04 |
2000-05-16 |
First; Eric R. |
Application of botulinum toxin to the management of neurogenic inflammatory disorders
|
AU2340299A
(en)
|
1998-01-26 |
1999-08-09 |
University Of Massachusetts |
Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
|
US7537773B1
(en)
|
1998-08-25 |
2009-05-26 |
Botulinum Toxin Research Associates, Inc. |
Chemodenervating pharmaceutical as anti-inflammatory agent
|
US6139545A
(en)
|
1998-09-09 |
2000-10-31 |
Vidaderm |
Systems and methods for ablating discrete motor nerve regions
|
TW574036B
(en)
|
1998-09-11 |
2004-02-01 |
Elan Pharm Inc |
Stable liquid compositions of botulinum toxin
|
AUPP627498A0
(en)
*
|
1998-10-02 |
1998-10-22 |
University Of Queensland, The |
Novel peptides - i
|
EP1135094B1
(en)
*
|
1999-04-16 |
2009-03-11 |
Marvin Schwartz |
Method to reduce hair loss and stimulate hair regrowth
|
DE19925739A1
(de)
|
1999-06-07 |
2000-12-21 |
Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh |
Therapeutikum mit einem Botulinum-Neurotoxin
|
US6767544B2
(en)
*
|
2002-04-01 |
2004-07-27 |
Allergan, Inc. |
Methods for treating cardiovascular diseases with botulinum toxin
|
US6113915A
(en)
|
1999-10-12 |
2000-09-05 |
Allergan Sales, Inc. |
Methods for treating pain
|
US6265379B1
(en)
*
|
1999-10-13 |
2001-07-24 |
Allergan Sales, Inc. |
Method for treating otic disorders
|
US7838008B2
(en)
|
1999-12-07 |
2010-11-23 |
Allergan, Inc. |
Methods for treating diverse cancers
|
US7838007B2
(en)
|
1999-12-07 |
2010-11-23 |
Allergan, Inc. |
Methods for treating mammary gland disorders
|
US6429189B1
(en)
|
1999-12-10 |
2002-08-06 |
Botulinum Toxin Research Associates, Inc. |
Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
|
US6500436B2
(en)
|
2000-01-19 |
2002-12-31 |
Allergan, Inc. |
Clostridial toxin derivatives and methods for treating pain
|
US6641820B1
(en)
|
2000-01-19 |
2003-11-04 |
Allergan, Inc. |
Clostridial toxin derivatives and methods to treat pain
|
US7138127B1
(en)
*
|
2000-01-19 |
2006-11-21 |
Allergan, Inc. |
Clostridial toxin derivatives and methods for treating pain
|
EP1398038B2
(en)
*
|
2000-02-08 |
2011-01-26 |
Allergan, Inc. |
Botulinum toxin pharmaceutical compositions
|
US7780967B2
(en)
|
2000-02-08 |
2010-08-24 |
Allergan, Inc. |
Reduced toxicity Clostridial toxin pharmaceutical compositions
|
US8632785B2
(en)
*
|
2000-02-08 |
2014-01-21 |
Allergan, Inc. |
Clostridial toxin pharmaceutical composition containing a gelatin fragment
|
US20030118598A1
(en)
*
|
2000-02-08 |
2003-06-26 |
Allergan, Inc. |
Clostridial toxin pharmaceutical compositions
|
US20060269575A1
(en)
*
|
2000-02-08 |
2006-11-30 |
Allergan, Inc. |
Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
|
US6821520B2
(en)
*
|
2000-02-15 |
2004-11-23 |
Allergan, Inc. |
Clostridial toxin therapy for Hashimoto's thyroiditis
|
US6753315B2
(en)
*
|
2000-02-24 |
2004-06-22 |
Brown University Research Foundation |
α-bungarotoxin molecules and uses thereof
|
US6464986B1
(en)
*
|
2000-04-14 |
2002-10-15 |
Allegan Sales, Inc. |
Method for treating pain by peripheral administration of a neurotoxin
|
US6299893B1
(en)
*
|
2000-04-17 |
2001-10-09 |
Marvin Schwartz |
Method to reduce hair loss and stimulate hair regrowth
|
US6565870B1
(en)
|
2000-04-28 |
2003-05-20 |
Allergan, Inc. |
Methods for treating bone tumors
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US20040170665A1
(en)
*
|
2000-06-02 |
2004-09-02 |
Allergan, Inc. |
Intravitreal botulinum toxin implant
|
MXPA03000014A
(es)
*
|
2000-06-28 |
2004-09-13 |
Ira Sanders |
Metodos para utilizar con fines beneficiosos toxina tetanica en animales.
|
US6903187B1
(en)
*
|
2000-07-21 |
2005-06-07 |
Allergan, Inc. |
Leucine-based motif and clostridial neurotoxins
|
US7691983B2
(en)
|
2000-07-21 |
2010-04-06 |
Allergan, Inc. |
Chimera botulinum toxin type E
|
US7491799B2
(en)
*
|
2000-07-21 |
2009-02-17 |
Allergan, Inc. |
Modified botulinum neurotoxins
|
US20040219619A1
(en)
*
|
2000-07-21 |
2004-11-04 |
Ester Fernandez-Salas |
Methods of identifying compounds that alter toxin persistence and/or protease activity
|
US7223577B2
(en)
*
|
2000-11-17 |
2007-05-29 |
Allergan, Inc. |
Post-translational modifications and Clostridial neurotoxins
|
US20020127247A1
(en)
|
2000-11-17 |
2002-09-12 |
Allergen Sales, Inc. |
Modified clostridial neurotoxins with altered biological persistence
|
US20020086036A1
(en)
|
2000-12-05 |
2002-07-04 |
Allergan Sales, Inc. |
Methods for treating hyperhidrosis
|
US7255865B2
(en)
|
2000-12-05 |
2007-08-14 |
Allergan, Inc. |
Methods of administering botulinum toxin
|
US20020192239A1
(en)
*
|
2001-01-09 |
2002-12-19 |
Borodic Gary E. |
Use of botulinum toxin for the treatment of chronic facial pain
|
JP4707254B2
(ja)
*
|
2001-04-24 |
2011-06-22 |
クミアイ化学工業株式会社 |
粒状組成物及びその製造方法
|
US7255866B2
(en)
|
2001-09-17 |
2007-08-14 |
Allergan, Inc. |
Botulinum toxin therapy for fibromyalgia
|
US6623742B2
(en)
|
2001-09-17 |
2003-09-23 |
Allergan, Inc. |
Methods for treating fibromyalgia
|
CA2466697C
(en)
|
2001-11-15 |
2013-09-24 |
Micro Algae Corporation |
Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
|
US7022329B2
(en)
*
|
2002-02-25 |
2006-04-04 |
Allergan, Inc. |
Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
|
EP1487481A4
(en)
*
|
2002-03-01 |
2005-11-23 |
Elan Pharm Inc |
METHOD FOR TREATING NERVE TERMINATION SYNDROMES
|
US6688311B2
(en)
*
|
2002-03-14 |
2004-02-10 |
Allergan, Inc. |
Method for determining effect of a clostridial toxin upon a muscle
|
US7140371B2
(en)
*
|
2002-03-14 |
2006-11-28 |
Allergan, Inc. |
Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
|
US6921538B2
(en)
*
|
2002-05-10 |
2005-07-26 |
Allergan, Inc. |
Therapeutic treatments for neuropsychiatric disorders
|
US7691394B2
(en)
*
|
2002-05-28 |
2010-04-06 |
Botulinum Toxin Research Associates, Inc. |
High-potency botulinum toxin formulations
|
CA2501856A1
(en)
*
|
2002-10-15 |
2004-04-29 |
Allergan, Inc. |
Botulinum toxin dental therapies and procedures
|
US7238357B2
(en)
*
|
2002-11-05 |
2007-07-03 |
Allergan, Inc. |
Methods for treating ulcers and gastroesophageal reflux disease
|
US20040086532A1
(en)
*
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
US7758872B1
(en)
*
|
2003-02-07 |
2010-07-20 |
Eric Finzi |
Method of treating depression
|
US20060153876A1
(en)
*
|
2003-02-24 |
2006-07-13 |
Ira Sanders |
Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
|
US8071550B2
(en)
*
|
2003-03-03 |
2011-12-06 |
Allergan, Inc. |
Methods for treating uterine disorders
|
US7670608B2
(en)
*
|
2003-03-06 |
2010-03-02 |
Botulinum Toxin Research Associates, Inc. |
Selection of patients with increased responsiveness to botulinum toxin
|
BRPI0408131A
(pt)
*
|
2003-03-06 |
2006-03-01 |
Botulinum Toxin Res Ass Inc |
tratamento com toxina botulina de dor facial e cefaléia crÈnicas relacionadas com sinusite
|
US20040247623A1
(en)
*
|
2003-03-24 |
2004-12-09 |
Roger Cady |
Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
|
AU2004231966A1
(en)
*
|
2003-04-16 |
2004-11-04 |
Allergan, Inc. |
Controlled volume injection/aspiration device
|
US7393538B2
(en)
*
|
2003-04-25 |
2008-07-01 |
Ackerman Alan H |
Clostridial toxin treatment for dermatillomania
|
US7393537B2
(en)
|
2003-04-25 |
2008-07-01 |
Allergan, Inc. |
Botulinum toxin for treatment of obsessive compulsive finger biting disorder
|
US7390496B2
(en)
*
|
2003-04-25 |
2008-06-24 |
Allergan, Inc. |
Therapeutic treatments for repetitive hand washing
|
US7422753B2
(en)
*
|
2003-04-25 |
2008-09-09 |
Allergan, Inc. |
Methods for treating trichotillomania
|
US7396535B2
(en)
*
|
2003-04-25 |
2008-07-08 |
Ackerman Alan H |
Therapy for obsessive compulsive head banging
|
US6838434B2
(en)
*
|
2003-05-02 |
2005-01-04 |
Allergan, Inc. |
Methods for treating sinus headache
|
US7220422B2
(en)
|
2003-05-20 |
2007-05-22 |
Allergan, Inc. |
Methods and compositions for treating eye disorders
|
US20040253274A1
(en)
*
|
2003-06-11 |
2004-12-16 |
Allergan, Inc. |
Use of a clostridial toxin to reduce appetite
|
US20050013850A1
(en)
*
|
2003-07-15 |
2005-01-20 |
Caers Jan K. |
Device to assist hyperhydrosis therapy
|
US8617572B2
(en)
|
2003-10-29 |
2013-12-31 |
Allergan, Inc. |
Botulinum toxin treatments of depression
|
US8734810B2
(en)
|
2003-10-29 |
2014-05-27 |
Allergan, Inc. |
Botulinum toxin treatments of neurological and neuropsychiatric disorders
|
US7172764B2
(en)
*
|
2003-11-17 |
2007-02-06 |
Allergan, Inc. |
Rescue agents for treating botulinum toxin intoxications
|
US8048423B2
(en)
*
|
2003-12-09 |
2011-11-01 |
Allergan, Inc. |
Botulinum toxin therapy for skin disorders
|
US8871224B2
(en)
|
2003-12-09 |
2014-10-28 |
Allergan, Inc. |
Botulinum toxin therapy for skin disorders
|
US20050129677A1
(en)
*
|
2003-12-10 |
2005-06-16 |
Shengwen Li |
Lipid rafts and clostridial toxins
|
US20050148935A1
(en)
*
|
2003-12-29 |
2005-07-07 |
Rozalina Dimitrova |
Botulinum toxin injection guide
|
US7270287B2
(en)
*
|
2004-01-06 |
2007-09-18 |
Allergan, Inc. |
Botulinum toxin treatment for kinesia
|
US6974579B2
(en)
*
|
2004-01-08 |
2005-12-13 |
Allergan, Inc. |
Methods for treating vascular disorders
|
US20100266638A1
(en)
|
2004-02-26 |
2010-10-21 |
Allergan, Inc. |
Headache treatment method
|
US9078892B2
(en)
|
2004-02-26 |
2015-07-14 |
Allergan, Inc. |
Methods for treating pain and for treating a medication overuse disorder
|
US20050191321A1
(en)
|
2004-02-26 |
2005-09-01 |
Allergan, Inc. |
Methods for treating headache
|
JP2007527431A
(ja)
*
|
2004-03-03 |
2007-09-27 |
ルバンス セラピュティックス |
局所的診断及び治療用の輸送のための組成物及び方法
|
US9211248B2
(en)
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
US20050220821A1
(en)
*
|
2004-03-31 |
2005-10-06 |
Allergan, Inc. |
Pressure sore treatment
|
US20050220734A1
(en)
*
|
2004-04-02 |
2005-10-06 |
Allergan, Inc. |
Therapy for melanin related afflictions
|
EP1802250A4
(en)
*
|
2004-05-07 |
2008-07-02 |
Phytotox Ltd |
METHOD FOR TREATING WOUNDS WITH GONYAUTOXINES
|
EP1796676B1
(en)
*
|
2004-05-07 |
2016-03-09 |
Phytotox Limited |
Transdermal administration of phycotoxins
|
US6991789B2
(en)
*
|
2004-06-29 |
2006-01-31 |
Allergas, Inc. |
Methods of modulating intracellular degradation rates of toxins
|
US7811584B2
(en)
|
2004-06-30 |
2010-10-12 |
Allergan, Inc. |
Multivalent clostridial toxins
|
US7922983B2
(en)
*
|
2005-07-28 |
2011-04-12 |
Kimberly-Clark Worldwide, Inc. |
Sterilization wrap with additional strength sheet
|
CN102908361A
(zh)
|
2004-07-09 |
2013-02-06 |
罗伯特·萨宾 |
治疗哺乳动物疾病的组合物及使用方法
|
US20070258900A1
(en)
*
|
2004-07-20 |
2007-11-08 |
Joseph Francis |
Blood Flow Assessment of Clostridial Toxin Applications
|
WO2006130161A2
(en)
*
|
2004-07-21 |
2006-12-07 |
The Cornell Research Foundation, Inc. |
Therapeutic compounds derived from spider venom and their method of use
|
US20060024794A1
(en)
*
|
2004-07-30 |
2006-02-02 |
Shengwen Li |
Novel methods for production of di-chain botulinum toxin
|
US20060024331A1
(en)
*
|
2004-08-02 |
2006-02-02 |
Ester Fernandez-Salas |
Toxin compounds with enhanced membrane translocation characteristics
|
US7429386B2
(en)
*
|
2004-09-03 |
2008-09-30 |
Allergan, Inc. |
Stretch mark treatment
|
US7179474B2
(en)
*
|
2004-09-03 |
2007-02-20 |
Allergan, Inc. |
Methods for treating a buttock deformity
|
US20060073208A1
(en)
*
|
2004-10-01 |
2006-04-06 |
Allergan, Inc. |
Cosmetic neurotoxin compositions and methods
|
US7897147B2
(en)
*
|
2004-10-20 |
2011-03-01 |
Allergan, Inc. |
Treatment of premenstrual disorders
|
AU2012241076B2
(en)
*
|
2005-02-01 |
2015-05-14 |
Allergan, Inc. |
Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
|
US7655244B2
(en)
|
2005-02-01 |
2010-02-02 |
Allergan, Inc. |
Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
|
US7749515B2
(en)
|
2005-02-01 |
2010-07-06 |
Allergan, Inc. |
Targeted delivery of botulinum toxin to the sphenopalatine ganglion
|
BRPI0608249A2
(pt)
|
2005-03-03 |
2009-12-08 |
Revance Therapeutics Inc |
formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
|
CA2556796C
(en)
|
2005-03-03 |
2018-01-23 |
Allergan, Inc. |
Animal product free system and process for purifying a botulinum toxin
|
US7731411B2
(en)
*
|
2005-04-04 |
2010-06-08 |
Schlumberger Technology Corporation |
Circulating fluid system for powder fluidization and method of performing same
|
US20090214466A1
(en)
*
|
2005-05-09 |
2009-08-27 |
Levin Bruce H |
Methods of Alleviating Disorders and Their Associated Pain
|
US7419675B2
(en)
*
|
2005-05-26 |
2008-09-02 |
Allergan, Inc. |
Method for treating peritoneal adhesions
|
US8105611B2
(en)
*
|
2005-06-17 |
2012-01-31 |
Allergan, Inc. |
Treatment of autoimmune disorder with a neurotoxin
|
US7910116B2
(en)
*
|
2005-08-24 |
2011-03-22 |
Allergan, Inc. |
Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
|
DE102005058639A1
(de)
*
|
2005-12-07 |
2007-07-26 |
Armin Maurer |
Behandlung von Trichodynie und anschwellender Arteria temporalis superficialis
|
US7824694B2
(en)
*
|
2006-01-12 |
2010-11-02 |
Allergan, Inc. |
Methods for enhancing therapeutic effects of a neurotoxin
|
US20070178121A1
(en)
*
|
2006-01-27 |
2007-08-02 |
Allergan, Inc. |
Methods for enhancing skin treatments
|
US7794386B2
(en)
|
2006-03-15 |
2010-09-14 |
Allergan, Inc. |
Methods for facilitating weight loss
|
US20080021437A1
(en)
*
|
2006-04-27 |
2008-01-24 |
Boyd James P |
Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
|
US7811586B2
(en)
*
|
2006-05-02 |
2010-10-12 |
Allergan, Inc. |
Methods for alleviating testicular pain
|
CN101074935B
(zh)
*
|
2006-05-19 |
2011-03-23 |
清华大学 |
探测器阵列及设备
|
US9061025B2
(en)
*
|
2006-08-31 |
2015-06-23 |
Allergan, Inc. |
Methods for selecting headache patients responsive to botulinum toxin therapy
|
US20080092910A1
(en)
*
|
2006-10-18 |
2008-04-24 |
Allergan, Inc. |
Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
|
US20080113051A1
(en)
*
|
2006-11-13 |
2008-05-15 |
Allergan, Inc. |
Methods for alleviating tattoo pain
|
JP2010519211A
(ja)
*
|
2007-02-15 |
2010-06-03 |
アラーガン、インコーポレイテッド |
膀胱もしくは前立腺障害または多汗症を処置するためのボツリヌス毒素および酵素の使用
|
BRPI0819212A2
(pt)
*
|
2007-10-23 |
2015-06-16 |
Allergan Inc |
Métodos de tratamento de inflamação neurogênica crônica usando toxinas modificadas de clostrídio
|
US8470337B2
(en)
*
|
2008-03-13 |
2013-06-25 |
Allergan, Inc. |
Therapeutic treatments using botulinum neurotoxin
|
US8617571B2
(en)
|
2008-04-03 |
2013-12-31 |
Allergan, Inc. |
Suture line administration technique using botulinum toxin
|
ES2356883B1
(es)
*
|
2008-07-24 |
2012-02-22 |
Bcn Peptides, S.A. |
Composición para el tratamiento del dolor y/o la inflamación.
|
US20100028385A1
(en)
*
|
2008-08-04 |
2010-02-04 |
Allergan, Inc. |
Treatment of excess cerumen secretion
|
US8512715B2
(en)
|
2008-08-14 |
2013-08-20 |
The Cleveland Clinic Foundation |
Apparatus and method for treating a neuromuscular defect
|
US9204925B2
(en)
|
2008-08-14 |
2015-12-08 |
The Cleveland Clinic Foundation |
Apparatus and method for treating a neuromuscular defect
|
EP2364168A1
(en)
|
2008-12-04 |
2011-09-14 |
Botulinum Toxin Research Associates, Inc. |
Extended length botulinum toxin formulation for human or mammalian use
|
CA2774951C
(en)
|
2009-09-24 |
2014-12-16 |
Allergan, Inc. |
Method of treating osteoporosis with a neurotoxin
|
US8940308B2
(en)
|
2010-03-30 |
2015-01-27 |
Allergan, Inc. |
Methods for treating depression
|
AU2011315962B2
(en)
|
2010-10-14 |
2016-06-02 |
Allergan, Inc. |
Targeted delivery of Targeted Exocytosis Modulators to the sphenopalatine ganglion for treatment of headache disorders
|
WO2012103415A1
(en)
|
2011-01-28 |
2012-08-02 |
Allergan, Inc. |
Dosage regimen for the treatment of multiple disorders with botulinum toxins
|
US8697090B2
(en)
|
2011-05-05 |
2014-04-15 |
Allergan, Inc. |
Method of treating persistent genital arousal disorder with a neurotoxin
|
WO2012174123A1
(en)
|
2011-06-13 |
2012-12-20 |
Allergan, Inc. |
Treatment of psychological trauma
|
US8992941B2
(en)
|
2011-07-08 |
2015-03-31 |
Allergan, Inc. |
Method for treatment of esophageal spasm
|
WO2013009625A1
(en)
|
2011-07-08 |
2013-01-17 |
Allergan, Inc. |
Method for treatment of autonomic nervous system disorders
|
CN103813802A
(zh)
|
2011-07-14 |
2014-05-21 |
阿勒根公司 |
用于治疗与性活动相关的失禁的方法
|
BR112014001066A2
(pt)
|
2011-07-20 |
2017-02-21 |
Allergan Inc |
toxinas botulínicas para uso em um método para tratamento de depósitos adiposos
|
WO2013137969A1
(en)
|
2012-03-12 |
2013-09-19 |
Binder William J |
Treatment of migraine headaches with presynaptic neurotoxin
|
US8722060B2
(en)
*
|
2012-05-23 |
2014-05-13 |
William J. Binder |
Method of treating vertigo
|
US8617569B2
(en)
|
2012-03-12 |
2013-12-31 |
William J. Binder |
Treatment of migraine headache with diffusion of toxin in non-muscle related foraminal sites
|
ES2424294B1
(es)
|
2012-03-22 |
2014-07-21 |
Lipotec, S.A. |
Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
|
US9393291B2
(en)
|
2012-04-12 |
2016-07-19 |
Botulinum Toxin Research Associates, Inc. |
Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
|
EP2649985A1
(en)
|
2012-04-13 |
2013-10-16 |
Lipotec, S.A. |
Compounds which inhibit neuronal exocytosis (III)
|
MX356343B
(es)
|
2012-04-13 |
2018-05-23 |
Lubrizol Advanced Mat Inc |
Compuestos que inhiben la exocitosis neuronal (ii).
|
EP2649983A1
(en)
|
2012-04-13 |
2013-10-16 |
Lipotec, S.A. |
Compounds which inhibit neuronal exocytosis (II)
|
EP2649984A1
(en)
|
2012-04-13 |
2013-10-16 |
Lipotec, S.A. |
Compounds which inhibit neuronal exocytosis
|
WO2013180799A1
(en)
|
2012-05-30 |
2013-12-05 |
President And Fellows Of Harvard College |
Engineered botulinum neurotoxin
|
US20140120077A1
(en)
|
2012-10-28 |
2014-05-01 |
Revance Therapeutics, Inc. |
Compositions and Methods for Safe Treatment of Rhinitis
|
WO2014078724A1
(en)
|
2012-11-16 |
2014-05-22 |
Finzi Eric |
Treatment of post-traumatic stress disorder using botulinum toxin a
|
CA2907800A1
(en)
|
2013-03-22 |
2014-09-25 |
Lipotec S.A. |
Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
|
US10149893B2
(en)
|
2013-09-24 |
2018-12-11 |
Allergan, Inc. |
Methods for modifying progression of osteoarthritis
|
US9480731B2
(en)
|
2013-12-12 |
2016-11-01 |
Medy-Tox, Inc. |
Long lasting effect of new botulinum toxin formulations
|
US9216210B2
(en)
|
2013-12-23 |
2015-12-22 |
Dublin City University |
Multiprotease therapeutics for chronic pain
|
US11484580B2
(en)
|
2014-07-18 |
2022-11-01 |
Revance Therapeutics, Inc. |
Topical ocular preparation of botulinum toxin for use in ocular surface disease
|
US9901627B2
(en)
|
2014-07-18 |
2018-02-27 |
Revance Therapeutics, Inc. |
Topical ocular preparation of botulinum toxin for use in ocular surface disease
|
WO2016149092A1
(en)
|
2015-03-13 |
2016-09-22 |
Allergan, Inc. |
Improved injection paradigm for administration of botulinum toxins
|
WO2016154534A1
(en)
|
2015-03-26 |
2016-09-29 |
President And Fellows Of Harvard College |
Engineered botulinum neurotoxin
|
AU2017277905B2
(en)
|
2016-06-08 |
2022-04-14 |
Children's Medical Center Corporation |
Engineered Botulinum neurotoxins
|
FI3481852T3
(fi)
|
2016-07-08 |
2023-03-19 |
Childrens Medical Center |
Uusi botulinum-neurotoksiini ja sen johdannaisia
|
EP3504226A1
(en)
|
2016-08-24 |
2019-07-03 |
President and Fellows of Harvard College |
Engineered botulinum neurotoxin
|
WO2018038301A1
(en)
|
2016-08-26 |
2018-03-01 |
Hugel Inc. |
Stabilized liquid formulation of botulinum toxin and preparation method thereof
|
MX2019002835A
(es)
|
2016-09-13 |
2019-09-04 |
Allergan Inc |
Composiciones no proteínicas de toxina clostridial.
|
CN112105379A
(zh)
|
2017-09-29 |
2020-12-18 |
儿童医学中心公司 |
神经毒素样毒素及其用途
|
EP3470054B1
(en)
|
2017-10-11 |
2023-09-20 |
Hugel Inc. |
Microstructure formulation techniques for botulinum toxin
|
US10525111B2
(en)
|
2017-10-12 |
2020-01-07 |
Hugel, Inc. |
Microstructure formulation techniques for botulinum toxin
|
US10792400B2
(en)
|
2017-10-12 |
2020-10-06 |
Hugel Inc. |
Microstructure formulation techniques for botulinum toxin
|
LT3660509T
(lt)
|
2018-11-29 |
2022-05-10 |
Hugel Inc. |
Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti
|
WO2020146333A1
(en)
|
2019-01-07 |
2020-07-16 |
Azizzadeh Babak |
Treatment of stress disorders, including post-traumatic stress disorder, using acetylcholine release inhibiting neurotoxic proteins to reduce stress levels
|
AU2020340428A1
(en)
*
|
2019-08-30 |
2022-03-03 |
AEON Biopharma, Inc. |
Neurotoxin compositions for use in treating headache
|
GEP20247609B
(en)
|
2019-12-20 |
2024-03-11 |
Ipsen Biopharm Ltd |
Ethod of producing botulinum toxin
|
WO2021247890A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Miotox, Llc |
Zonal and targeted methods and uses for treating a migraine disorder
|